pisco_log
banner

Preoperative Hematological Markers for Subtype Classification of Newly Diagnosed IDH-mutant High-grade Gliomas

Xin Jia, Shiqi Lin, Xian Han, Zhiliang Wang, Xiaozhong Chen*

Abstract


Purpose: The purpose of our study is to explore the diagnostic value of the single and combined hematological maker for the classification of isocitrate dehydrogenase (IDH) 1/2 mutant high-grade gliomas (HGGs). Methods: A total of 60 newly diagnosed HGGs patients
were included in this study. Firstly, we compared the levels of hematology indicators in the classification of HGGs. Next, the correlation between the levels of hematology indicators with basic clinical features was analyzed. Finally, the diagnostic value of the single and combined
hematology indicator for identifying the classification from HGGs was performed. Results: The level of fibrinogen (FIB) was higher in World
Health Organization grade 4(G4). We found that the best single and combined indicator for identifying G4 from HGGs were FIB [0.615
(0.546-0.684)] and age+FIB [0.726 (0.662-0.791)], respectively. Conclusions: Preoperative hematological indicators have high diagnostic
value for G4 from HGGs, especially FIB combined age.

Keywords


High-grade gliomas; Preoperative hematological makers; Classification; IDH mutation

Full Text:

PDF

Included Database


References


[1] Louis D N, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary[J]. Neurooncology, 2021, 23 (8): 1231-1251.

[2] Horbinski C, Nabors L B, Portnow J, et al. NCCN Guidelines Insights: Central Nervous System Cancers, Version 2.2022[J]. Journal of

the National Comprehensive Cancer Network: JNCCN, 2023, 21 (1): 12-20.

[3] Hou S, Gu Q, Yang T, et al. A Multicenter Study on the Prognostic Value of Indicators Derived From Complete Blood Count in

Glioblastoma[J]. Mediators Inflamm, 2025, 2025: 5588098.

[4] Ajmi M, Riahi S, Ben Hassine I, et al. Complete blood count-derived biomarkers as indicators of systemic lupus erythematosus activity:

a cross-sectional comparative study[J]. Lupus Science & Medicine, 2025, 12 (2).

[5] Hasani F, Jazi K, Vakili K, et al. Peripheral Blood Leukocyte Ratios as Novel Biomarkers in Brain Glioma: A Comprehensive Systematic Review and Meta-Analysis[J]. J Cell Mol Med, 2026, 30 (1): e70974.

[6] Stepanenko A A, Sosnovtseva A O, Valikhov M P, et al. Systemic and local immunosuppression in glioblastoma and its prognostic

significance[J]. Front Immunol, 2024, 15: 1326753.

[7] Xu W-Z, Li F, Xu Z-K, et al. Preoperative albumin-to-globulin ratio and prognostic nutrition index predict prognosis for glioblastoma[J].

Onco Targets Ther, 2017, 10: 725-733.

[8] Zheng S-H, Huang J-L, Chen M, et al. Diagnostic value of preoperative inflammatory markers in patients with glioma: a multicenter cohort study[J]. Journal of Neurosurgery, 2017, 129 (3): 583-592.

[9] Wang P-F, Meng Z, Song H-W, et al. Preoperative Changes in Hematological Markers and Predictors of Glioma Grade and Survival[J].

Frontiers In Pharmacology, 2018, 9: 886.

[10] Jiang Y, Zhou L. Prognostic value of systemic inflammation response index in patients with glioma: a meta-analysis[J]. Front Immunol,

2025, 16: 1576845.

[11] Shao B, Wahrenbrock M G, Yao L, et al. Carcinoma mucins trigger reciprocal activation of platelets and neutrophils in a murine model

of Trousseau syndrome[J]. Blood, 2011, 118 (15): 4015-4023.




DOI: http://dx.doi.org/10.70711/pmr.v3i7.9422

Refbacks

  • There are currently no refbacks.